New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Acumen Pharmaceuticals, Inc. (ABOS) vs BioStem Technologies, Inc. (BSEM)

Acumen Pharmaceuticals, Inc. and BioStem Technologies, Inc. are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and BioStem Technologies, Inc. are of similar size ($14.0M and $13.6M). BioStem Technologies, Inc. has the higher net margin (−121.0% vs −510.1%) and the lower return on invested capital (−7.07% vs 0.00%). Across the 11 metrics below, Acumen Pharmaceuticals, Inc. leads on 6 and BioStem Technologies, Inc. on 5.

Valuation

Metric ABOS BSEM Biotechnology median
P/E n/m n/m 8.49
P/S 9.07 0.36 8.56
P/B 0.38 0.62 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 0.38 n/m 0.69
EV/Sales (27.38) 0.33 8.00
Earnings yield (855.56%) (348.67%) (35.81%)
Free cash flow yield (675.63%) — (25.41%)

Profitability

Metric ABOS BSEM Biotechnology median
Gross margin 100.00% 79.83% 70.18%
Operating margin (550.97%) (6.18%) 0.00%
Net margin (510.10%) (121.02%) 0.00%
Free cash flow margin (518.80%) — 0.00%
Return on equity (162.72%) — (51.58%)
Return on assets (91.28%) — (45.91%)
Return on invested capital 0.00% (7.07%) 0.00%

Growth

Metric ABOS BSEM Biotechnology median
Revenue growth (TTM) — (83.87%) 7.20%
EPS growth (last fiscal year) (16.96%) (126.53%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ABOS BSEM Biotechnology median
Debt to equity 0.76 0.00 0.00
Current ratio 1.89 0.73 4.79
Net debt to EBITDA 0.69 — 1.01

Dividend

Metric ABOS BSEM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABOS BSEM Biotechnology median
Market cap 13.98m 13.57m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack